{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T23:00:02Z","timestamp":1785538802943,"version":"3.56.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,7]],"date-time":"2022-08-07T00:00:00Z","timestamp":1659830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,7]],"date-time":"2022-08-07T00:00:00Z","timestamp":1659830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009431","name":"Baxalta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009431","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Allergy Asthma Clin Immunol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Real-world data on transitioning to Immune Globulin Subcutaneous (Human) 20% solution (Ig20Gly) are limited. This study aimed to assess infusion parameters and experience of patients with primary (PID) or secondary immunodeficiencies (SID) transitioning to Ig20Gly in clinical practice in Canada.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients with PID or SID who received subcutaneous immunoglobulin (SCIG) for\u2009\u2265\u20093\u00a0months before transitioning to Ig20Gly were eligible for this multicenter (n\u2009=\u20096), phase 4, non-interventional, prospective, single-arm study. Ig20Gly infusion parameters, dosing, and adverse events were collected from patient medical records at Ig20Gly initiation and 3, 6, and 12\u00a0months post-initiation. Patient satisfaction and quality of life were assessed 12\u00a0months post-initiation using validated questionnaires.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The study included 125 patients (PID, n\u2009=\u200960; SID, n\u2009=\u200964; PID\u2009+\u2009SID, n\u2009=\u20091). Median volume per infusion was 30.0\u00a0ml at initiation, and 40.0\u00a0ml at 6 and 12\u00a0months post-initiation. Most patients administered Ig20Gly weekly and used two infusion sites (primarily abdomen). At each time point, median infusion duration was\u2009\u2264\u20091\u00a0h. At 12\u00a0months, 61% of infusions were administered via a pump and 39% manually. Headache and infusion-site reactions were the most reported adverse events of interest. Patients expressed overall satisfaction with Ig20Gly at 12\u00a0months post-initiation, with all respondents indicating they would like to continue Ig20Gly.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study provides a detailed description of Ig20Gly infusion parameters, tolerability, and quality of life in clinical practice among patients with PID or SID switching to Ig20Gly from another SCIG and confirms the feasibility of infusing Ig20Gly via pump or manual administration.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> NCT03716700, Registered 31 August 2018, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03716700\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03716700<\/jats:ext-link><\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13223-022-00709-8","type":"journal-article","created":{"date-parts":[[2022,8,7]],"date-time":"2022-08-07T14:02:21Z","timestamp":1659880941000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real-world study"],"prefix":"10.1186","volume":"18","author":[{"given":"Paul K.","family":"Keith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juthaporn","family":"Cowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Kanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Lacuesta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9025-5626","authenticated-orcid":false,"given":"Andr\u00e9","family":"Gladiator","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,7]]},"reference":[{"key":"709_CR1","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1007\/s10875-021-00980-1","volume":"41","author":"SG Tangye","year":"2021","unstructured":"Tangye SG, Al-Herz W, Bousfiha A, Cunningham-Rundles C, Franco JL, Holland SM, et al. The Ever-increasing array of novel inborn errors of immunity: an interim update by the IUIS committee. J Clin Immunol. 2021;41:666\u201379.","journal-title":"J Clin Immunol"},{"key":"709_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3389\/fimmu.2019.00033","volume":"10","author":"SY Patel","year":"2019","unstructured":"Patel SY, Carbone J, Jolles S. The expanding field of secondary antibody deficiency: causes, diagnosis, and management. Front Immunol. 2019;10:33.","journal-title":"Front Immunol"},{"issue":"1186\u2013205","key":"709_CR3","first-page":"e1","volume":"136","author":"FA Bonilla","year":"2015","unstructured":"Bonilla FA, Khan DA, Ballas ZK, Chinen J, Frank MM, Hsu JT, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015;136(1186\u2013205):e1-78.","journal-title":"J Allergy Clin Immunol"},{"key":"709_CR4","first-page":"76","volume":"6","author":"G Krivan","year":"2017","unstructured":"Krivan G, Jolles S, Granados EL, Paolantonacci P, Ouaja R, Cisse OA, et al. New insights in the use of immunoglobulins for the management of immune deficiency (PID) patients. Am J Clin Exp Immunol. 2017;6:76\u201383.","journal-title":"Am J Clin Exp Immunol"},{"key":"709_CR5","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.2217\/imt-2017-0092","volume":"9","author":"RL Wasserman","year":"2017","unstructured":"Wasserman RL. Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases. Immunotherapy. 2017;9:1035\u201350.","journal-title":"Immunotherapy"},{"key":"709_CR6","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/ejh.13580","volume":"106","author":"S Jolles","year":"2021","unstructured":"Jolles S, Michallet M, Agostini C, Albert MH, Edgar D, Ria R, et al. Treating secondary antibody deficiency in patients with haematological malignancy: European expert consensus. Eur J Haematol. 2021;106:439\u201349.","journal-title":"Eur J Haematol"},{"key":"709_CR7","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1080\/1744666X.2020.1807328","volume":"16","author":"C Monle\u00f3n Bonet","year":"2020","unstructured":"Monle\u00f3n Bonet C, Waser N, Cheng K, Tzivelekis S, Edgar JDM, Sanchez-Ramon S. A systematic literature review of the effects of immunoglobulin replacement therapy on the burden of secondary immunodeficiency diseases associated with hematological malignancies and stem cell transplants. Expert Rev Clin Immunol. 2020;16:911\u201321.","journal-title":"Expert Rev Clin Immunol"},{"key":"709_CR8","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1097\/SMJ.0b013e3181eba6ea","volume":"103","author":"M Berger","year":"2010","unstructured":"Berger M, Murphy E, Riley P, Bergman GE. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G. South Med J. 2010;103:856\u201363.","journal-title":"South Med J"},{"issue":"Suppl 1","key":"709_CR9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1365-2249.2009.04027.x","volume":"158","author":"S Misbah","year":"2009","unstructured":"Misbah S, Sturzenegger MH, Borte M, Shapiro RS, Wasserman RL, Berger M, et al. Subcutaneous immunoglobulin: opportunities and outlook. Clin Exp Immunol. 2009;158(Suppl 1):51\u20139.","journal-title":"Clin Exp Immunol"},{"key":"709_CR10","unstructured":"US Food and Drug Administration. CUVITRU, immune globulin subcutaneous (human), 20% solution: prescribing information. https:\/\/www.fda.gov\/media\/100531\/download. Accessed 23 Feb 2022."},{"key":"709_CR11","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s10875-012-9740-x","volume":"32","author":"RL Wasserman","year":"2012","unstructured":"Wasserman RL. Progress in gammaglobulin therapy for immunodeficiency: from subcutaneous to intravenous infusions and back again. J Clin Immunol. 2012;32:1153\u201364.","journal-title":"J Clin Immunol"},{"key":"709_CR12","unstructured":"Cuvitru 200 mg\/ml solution for subcutaneous injection: summary of product characteristics. https:\/\/www.medicines.org.uk\/emc\/product\/9191\/smpc. Accessed 23 Feb 2022."},{"key":"709_CR13","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/cei.12866","volume":"187","author":"M Borte","year":"2017","unstructured":"Borte M, Krivan G, Derfalvi B, Marodi L, Harrer T, Jolles S, et al. Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2\/3 study in Europe in patients with primary immunodeficiencies. Clin Exp Immunol. 2017;187:146\u201359.","journal-title":"Clin Exp Immunol"},{"key":"709_CR14","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1007\/s10875-016-0327-9","volume":"36","author":"D Suez","year":"2016","unstructured":"Suez D, Stein M, Gupta S, Hussain I, Melamed I, Paris K, et al. Efficacy, safety, and pharmacokinetics of a novel human immune globulin subcutaneous, 20 % in patients with primary immunodeficiency diseases in North America. J Clin Immunol. 2016;36:700\u201312.","journal-title":"J Clin Immunol"},{"key":"709_CR15","unstructured":"Canadian Blood Services. Plasma protein products request for proposal results [Internet]. https:\/\/www.blood.ca\/sites\/default\/files\/CL_2017-42.pdf. Accessed 23 Feb 2022."},{"key":"709_CR16","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1006\/clim.1999.4799","volume":"93","author":"ME Conley","year":"1999","unstructured":"Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol. 1999;93:190\u20137.","journal-title":"Clin Immunol"},{"key":"709_CR17","unstructured":"Shire Pharma Canada ULC. CUVITRU product monograph. https:\/\/pdf.hres.ca\/dpd_pm\/00044942.PDF. Accessed 23 Feb 2022."},{"key":"709_CR18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1477-7525-2-12","volume":"2","author":"MJ Atkinson","year":"2004","unstructured":"Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;2:12.","journal-title":"Health Qual Life Outcomes"},{"key":"709_CR19","first-page":"504","volume":"67","author":"PB Daly","year":"1991","unstructured":"Daly PB, Evans JH, Kobayashi RH, Kobayashi AL, Ochs HD, Fischer SH, et al. Home-based immunoglobulin infusion therapy: quality of life and patient health perceptions. Ann Allergy. 1991;67:504\u201310.","journal-title":"Ann Allergy"},{"key":"709_CR20","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1007\/s11136-005-1746-x","volume":"14","author":"U Nicolay","year":"2005","unstructured":"Nicolay U, Haag S, Eichmann F, Herget S, Spruck D, Gardulf A. Measuring treatment satisfaction in patients with primary immunodeficiency diseases receiving lifelong immunoglobulin replacement therapy. Qual Life Res. 2005;14:1683\u201391.","journal-title":"Qual Life Res"},{"key":"709_CR21","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.anai.2021.06.023","volume":"127","author":"LM Meckley","year":"2021","unstructured":"Meckley LM, Wu Y, Tzivelekis S, Gandhi V, Gladiator A. Infusion parameters of 20% subcutaneous immunoglobulin for primary immunodeficiency diseases among patient support program participants. Ann Allergy Asthma Immunol. 2021;127:568-74.e1.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"709_CR22","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/pai.12026","volume":"24","author":"RS Shapiro","year":"2013","unstructured":"Shapiro RS. Subcutaneous immunoglobulin: rapid push vs infusion pump in pediatrics. Pediatr Allergy Immunol. 2013;24:49\u201353.","journal-title":"Pediatr Allergy Immunol"},{"key":"709_CR23","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s10875-009-9352-2","volume":"30","author":"R Shapiro","year":"2010","unstructured":"Shapiro R. Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis. J Clin Immunol. 2010;30:301\u20137.","journal-title":"J Clin Immunol"},{"key":"709_CR24","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/cei.12099","volume":"173","author":"R Shapiro","year":"2013","unstructured":"Shapiro R. Subcutaneous immunoglobulin (16 or 20%) therapy in obese patients with primary immunodeficiency: a retrospective analysis of administration by infusion pump or subcutaneous rapid push. Clin Exp Immunol. 2013;173:365\u201371.","journal-title":"Clin Exp Immunol"},{"key":"709_CR25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.anai.2013.04.015","volume":"111","author":"RS Shapiro","year":"2013","unstructured":"Shapiro RS. Subcutaneous immunoglobulin therapy given by subcutaneous rapid push vs infusion pump: a retrospective analysis. Ann Allergy Asthma Immunol. 2013;111:51\u20135.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"709_CR26","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/j.1365-2249.2012.04594.x","volume":"169","author":"JS Orange","year":"2012","unstructured":"Orange JS, Belohradsky BH, Berger M, Borte M, Hagan J, Jolles S, et al. Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy. Clin Exp Immunol. 2012;169:172\u201381.","journal-title":"Clin Exp Immunol"},{"key":"709_CR27","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ijantimicag.2010.11.027","volume":"37","author":"LJ Maarschalk-Ellerbroek","year":"2011","unstructured":"Maarschalk-Ellerbroek LJ, Hoepelman IM, Ellerbroek PM. Immunoglobulin treatment in primary antibody deficiency. Int J Antimicrob Agents. 2011;37:396\u2013404.","journal-title":"Int J Antimicrob Agents"},{"key":"709_CR28","doi-asserted-by":"publisher","first-page":"S525","DOI":"10.1016\/j.jaci.2006.01.015","volume":"117","author":"JS Orange","year":"2006","unstructured":"Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2006;117:S525\u201353.","journal-title":"J Allergy Clin Immunol"},{"key":"709_CR29","unstructured":"Canadian Immunodeficiencies Patient Organization. IG Transition report [Internet]. http:\/\/www.cipo.ca\/wp-content\/uploads\/2019\/01\/Final-Report-IG-Transition.pdf. Accessed February 23, 2022."}],"updated-by":[{"DOI":"10.1186\/s13223-023-00805-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T00:00:00Z","timestamp":1687478400000}}],"container-title":["Allergy, Asthma &amp; Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-022-00709-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13223-022-00709-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-022-00709-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T05:39:09Z","timestamp":1687585149000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacijournal.biomedcentral.com\/articles\/10.1186\/s13223-022-00709-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,7]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["709"],"URL":"https:\/\/doi.org\/10.1186\/s13223-022-00709-8","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s13223-023-00805-3","asserted-by":"object"}]},"ISSN":["1710-1492"],"issn-type":[{"value":"1710-1492","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,7]]},"assertion":[{"value":"10 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13223-023-00805-3","URL":"https:\/\/doi.org\/10.1186\/s13223-023-00805-3","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional review board approval was obtained centrally (by Advarra), and locally at each site prior to site initiation. The study is registered on ClinicalTrials.gov under the identifier NCT03716700. All patients provided written informed consent prior to study enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PKK has received personal fees from Novartis, Aralez Pharmaceuticals, Pediapharm, AstraZeneca, Shire, CSL Behring, Kaleo, Merck, GlaxoSmithKline, Mylan, ALK, Sanofi, and Stallergenes and grants from AstraZeneca, CSL Behring, Genentech, and Shire. JCo has received research funding not related to this study from CSL Behring, Grifols, and Octapharma. She has received speaker fees from Octapharma, GSK, EMD Serono, and Alexion Pharma. She has received educational funding from Takeda. AK has received personal fees from Novartis, Aralez Pharmaceuticals, Pediapharm, Takeda, CSL Behring, and Mylan. He has received grants from Genentech and Takeda. HK has been on speakers\u2019 bureaus and\/or advisory boards for ALK, AstraZeneca, Aralez, CSL Behring, Kaleo, Merck, Mylan, Novartis, Pediapharm, Sanofi, and Shire. He has received research funding from AstraZeneca, Shire, and Novartis. GL has participated in research with Takeda. She has received speaker fees from Takeda, CSL Behring, Novartis, AstraZeneca, and Mylan. She has participated in advisory boards for Takeda, CSL Behring, Octapharma, Sanofi, GSK, and AstraZeneca; and was sponsored to attend international meetings with Shire\/Takeda, AstraZeneca, and GSK. JKL has received speaker fees from ALK, Paladin, Novartis, AstraZeneca, Sanofi, Astellas, GSK, Takeda, Merck, CSL Behring, Omega, Sanofi Genzyme, Mylan, Meda, Pediapharm, Aralez, Paladin, Pfizer, and Stallergenes. He has received grants and research funding from Immunodeficiency Canada, AstraZeneca, ALK, Aralez, Paladin, Novartis, Sanofi, CSL Behring, GSK, Pediapharm, Stallergenes, Roche-Genentech, PPD, Shire, Takeda, Trudell Medical, Bausch and Lomb, and Regeneron. He has participated in advisory boards for GSK, Novartis, AstraZeneca, Merck, CSL Behring, Teva, Sanofi Genzyme, Mylan, ALK, Meda, Pediapharm, Paladin, Regeneron, AbbVie, and Genentech. He has been a consultant for GSK, AstraZeneca, Novartis, Regeneron, and Sanofi Genzyme. JCh and MP are employees of Takeda Development Center Americas, Inc. and are Takeda shareholders. AG is an employee of Takeda Pharmaceuticals International AG and a Takeda shareholder.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"70"}}